EUnetHTA 21 shares draft on medicinal JCA timelines in D5.4 deliverable

By HEOR Staff Writer

July 4, 2023

The objective is to produce Joint Clinical Assessments (JCA) for medicinal products and medical devices in order to improve quality, consistency, and national adoption of the JCA. The production process will be standardized. During the production, the methodological convergence paths defined in EUnetHTA JA3 will be tested, including the PICO concept paper and the GRADE framework paper. Additionally, the new methodological guidelines developed by EUnetHTA 21, as well as revised templates and guidelines, will be tested to address challenges identified in EUnetHTA JA3.

 

Read the draft document here: on the link below

Join the discussion on July 13th, 2023. Register now via Eventbrite at https://www.eventbrite.co.uk/e/eunethta-21-htd-meeting-tickets-647889433737?aff=oddtdtcreator 

Reference url

Recent Posts

Advancements in Continuous Glucose Monitoring for Type 2 Diabetes Management

By HEOR Staff Writer

November 27, 2025

Advancements in CGM for Type 2 Diabetes Management A recent JAMA Insights article, explores the integration of continuous glucose monitoring as a complementary tool to traditional hemoglobin A1c (HbA1c) an...
NICE Endorses Obecabtagene Autoleucel Therapy for Adult Relapsed B-Cell Leukaemia

By João L. Carapinha

November 25, 2025

NICE Backs Obecabtagene Autoleucel The National Institute for Health and Care Excellence (NICE) recommended obecabtagene autoleucel therapy, a UK-developed chimeric antigen receptor (CAR) T-cell trea...
Rethinking HEOR Market Access Integration: A Call for Early Engagement Before Phase 3

By João L. Carapinha

November 24, 2025

Early HEOR Market Access Integration In this brief interview on ISPOR, Indranil Bagchi asserts that HEOR market access integration must occur earlier in drug development—ideally before Ph...